Glyxambi Lawyers No Longer Reviewing New Cases
The product liability lawyers at Saiontz & Kirk, P.A. are no longer accepting additional Glyxambi cases. Lawsuits were previously evaluated for individuals who suffered kidney failure or were hospitalized to diabetic ketoacidosis (DKA), ketosis or acidosis after using this new-generation diabetes drug. This page is maintained for informational purposes only.
Glyxambi (empagliflozin and linagliptin) is a combination drug introduced by Boehringer Ingelheim in early 2015, for treatment of type 2 diabetes. The medication is part of a new generation of diabetes drugs, which have been linked to a number of serious and potentially life-threatening side effects.
The medication includes the active ingredients in Jardiance and Tradjenta, and was the sixth member of a new class of diabetes drugs that have hit the market since 2013.
The medications work by inhibiting some kidney functions to increase the amount of sugar excreted in the urine. This was designed to increase glucose production and lower blood glucose levels among diabetics. The addition of Tradjenta decreases the production of incretin hormones known as glucagon-like peptide-1.
Although information about the potential injury risk of certain side effects of Glyxambi were known or should have been suspected before the medication was introduced, it appears that the drug maker failed to provide adequate warnings for consumers and the medical community.
▸ Glyxambi Kidney Failure Problems
Adverse event reports involving problems with Glyxambi or other SGLT2 inhibitors suggest that the medication may carry a potential risk of kidney problems.
During the first year that the similar drug Invokana was on the market, many users reported suffering:
- Kidney Failure
- Kidney Impairment
- Kidney Stones
- Urinary Tract Infections
- Abnormal Weight Loss
- Hypersensitivity Reactions
As more users are switched to this new medication, it appears likely that similar Glyxambi problems will be reported. The similar mechanism of action for the new diabetes drug raises questions about why the potential link between Glyxambi and kidney failure was not suspected before the medication was ever sold.
▸ Glyxambi Ketoacidosis Risk
In May 2015, the FDA first issued a drug safety communication regarding Glyxambi and othersodium-glucose co-transporter 2 (SGLT2) inhibiting diabetes drugs, indicating that the agency was investigating reports of users suffering ketoacidosis.
Known as Diabetic Ketoacidosis (DKA), Ketosis or Acidosis, the problems involve the accumulation of high levels of acid in the blood, which can result in the need for emergency medical treatment or hospitalization. In December 2015, the FDA announced that stronger Glyxambi warnings will be required, indicating that patients should stop using the drug immediately and seek medical assistance if they began experiencing signs of ketoacidosis, such as:
- Difficulty Breathing
- Nausea or Vomiting
- Abdominal Pain
- Confusion, Fatigue or Sleepiness
The FDA highlighted at least 73 adverse event reports received involving ketoacidosis with Glyxambi or other similar diabetes drugs. Each of the cases resulted in hospitalization or emergency room treatment.
Glyxambi Class Action Lawyers
According to allegations raised in Glyxambi class action lawsuits and individual injury claims, the manufacturers of the diabetes drug may have placed their desire for profits before consumer safety, by rushing the medication to market to gain an advantage over other competitor diabetes drugs. It appears that the drug maker failed to properly research the risk of DKA (diabetic ketoacidosis) or kidney failure, and withheld important safety information about the risk of serious and potentially life-threatening health problems from Glyxambi.
New Glyxambi cases are no longer being accepted. This page is maintained for informational purposes only.